BRPI0818656A2 - Vacinas de citomegalovírus e métodos de produção - Google Patents

Vacinas de citomegalovírus e métodos de produção

Info

Publication number
BRPI0818656A2
BRPI0818656A2 BRPI0818656-1A BRPI0818656A BRPI0818656A2 BR PI0818656 A2 BRPI0818656 A2 BR PI0818656A2 BR PI0818656 A BRPI0818656 A BR PI0818656A BR PI0818656 A2 BRPI0818656 A2 BR PI0818656A2
Authority
BR
Brazil
Prior art keywords
production methods
cytomegalovirus vaccines
cytomegalovirus
vaccines
production
Prior art date
Application number
BRPI0818656-1A
Other languages
English (en)
Inventor
Thomas Shenk
Dai Wang
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Publication of BRPI0818656A2 publication Critical patent/BRPI0818656A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0818656-1A 2007-10-10 2008-10-10 Vacinas de citomegalovírus e métodos de produção BRPI0818656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99842607P 2007-10-10 2007-10-10
PCT/US2008/079494 WO2009049138A1 (en) 2007-10-10 2008-10-10 Cytomegalovirus vaccines and methods of production

Publications (1)

Publication Number Publication Date
BRPI0818656A2 true BRPI0818656A2 (pt) 2015-04-14

Family

ID=40549581

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818656-1A BRPI0818656A2 (pt) 2007-10-10 2008-10-10 Vacinas de citomegalovírus e métodos de produção

Country Status (15)

Country Link
US (2) US9439960B2 (pt)
EP (1) EP2200645B1 (pt)
JP (1) JP5409638B2 (pt)
KR (1) KR20100084627A (pt)
CN (1) CN101820906B (pt)
AU (1) AU2008310713B2 (pt)
BR (1) BRPI0818656A2 (pt)
CA (1) CA2701727C (pt)
IL (1) IL204850A0 (pt)
MX (1) MX2010003713A (pt)
NZ (1) NZ584459A (pt)
RU (1) RU2491340C2 (pt)
SG (1) SG185291A1 (pt)
WO (1) WO2009049138A1 (pt)
ZA (1) ZA201002216B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
RU2660712C2 (ru) * 2012-03-27 2018-07-09 Вэриэйшн Биотекнолоджиз, Инк. Способы детекции антицитомегаловирусных нейтрализующих антител
US9683022B2 (en) 2012-07-06 2017-06-20 Glaxosmithkline Biologicals S.A. Complexes of cytomegalovirus proteins
EP2877580B1 (en) 2012-07-27 2019-01-30 City of Hope An mva vaccine for delivery of a ul128 complex and preventing cmv infection
US9395369B2 (en) 2012-10-19 2016-07-19 Regents Of The University Of Minnesota Guinea pig cytomegalovirus (CIDMTR strain)
CN103937871B (zh) * 2013-01-23 2019-07-23 上海市东方医院 Srrp35基因和表达产物在癌症诊断与治疗中的应用
WO2015073788A2 (en) * 2013-11-15 2015-05-21 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3601544A4 (en) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDITION OF NUCLEASES DIRECTLY TO A CELL CULTURE TO PROMOTE DIGESTION AND ELIMINATION OF HOST CELL NUCLEIC ACIDS
WO2018193307A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CA3079828A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) * 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
US4058598A (en) * 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US6471965B1 (en) * 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2005012545A2 (en) 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
EP2037959B1 (en) * 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production

Also Published As

Publication number Publication date
US9439960B2 (en) 2016-09-13
EP2200645B1 (en) 2016-01-27
JP5409638B2 (ja) 2014-02-05
RU2491340C2 (ru) 2013-08-27
US10300130B2 (en) 2019-05-28
US20170014504A1 (en) 2017-01-19
US20100285059A1 (en) 2010-11-11
WO2009049138A1 (en) 2009-04-16
EP2200645A1 (en) 2010-06-30
KR20100084627A (ko) 2010-07-27
EP2200645A4 (en) 2012-07-11
JP2011500592A (ja) 2011-01-06
CN101820906B (zh) 2015-04-22
CN101820906A (zh) 2010-09-01
CA2701727A1 (en) 2009-04-16
SG185291A1 (en) 2012-11-29
AU2008310713B2 (en) 2012-06-14
MX2010003713A (es) 2010-08-02
RU2010117741A (ru) 2011-11-20
IL204850A0 (en) 2010-11-30
ZA201002216B (en) 2011-06-29
AU2008310713A1 (en) 2009-04-16
CA2701727C (en) 2016-12-13
NZ584459A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
BRPI0818656A2 (pt) Vacinas de citomegalovírus e métodos de produção
DK2200646T3 (da) RNA-Vacciner
DK2049559T3 (da) Forbedrede HPV vacciner
ATE450271T1 (de) Impfstoff
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
DK2114993T3 (da) Vaccine
EP2501439A4 (en) FAN
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
HUE041436T2 (hu) Tal-effektor-közvetített DNS-módosítás
BRPI1006537A2 (pt) método e artigo
BR112012004593A2 (pt) "método"
DK2132326T3 (da) Fremgangsmåder
DK2265527T3 (da) Sorteringsindretning
BRPI0814876A2 (pt) Análogos de pirona fosforilados e métodos
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI0911625A2 (pt) Métodos
BRPI0908183A2 (pt) membro embalado e método de produção do mesmo
EP2257169A4 (en) TETRAHYDROTHIENPYRIDINE
ZA201001029B (en) Vaccines
BRPI0809678A2 (pt) Métodos
FI20090142A0 (fi) Uudet menetelmät ja tuotteet
BRPI0810416A2 (pt) Método de hidroformação
BRPI0911364A2 (pt) tienopirimidinas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]